Over the course of a decade, Stout performed numerous valuations for a large, publicly traded global pharmaceutical and medical device company. The company was the world's largest producer of generic injectable pharmaceuticals, manufacturing generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management systems. We worked closely with the CFO and corporate controller regarding the valuations of 10 reporting units related to the company’s annual goodwill impairment testing. In addition to valuing each reporting unit, we performed a reconciliation to the company’s market capitalization. We also developed multiple sensitivity analyses with varying forecasts and discount rates, which the CFO presented to the board of directors audit committee.